SmartPharm Therapeutics Inc. is a privately-held, development-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of serious or rare diseases with the vision of creating “biologics from within.” The Company is currently developing a novel pipeline of non-viral, gene-encoded proteins for the treatment of conditions that require enzyme replacement therapy and tissue restoration. SmartPharm commenced operations in 2018 and is headquartered in Cambridge, MA, USA.
